Clinical Application of a Dendritic Cell Vaccine Raised Against Heat-Shocked Glioblastoma
Clinical Application of a Dendritic Cell Vaccine Raised Against Heat-Shocked Glioblastoma
复制标题
DOI：
10.1007/s12013-011-9265-6
复制
发表时间：
2012-01-01
影响因子：
2.6
通讯作者：
Hua, Z.
中科院分区：
文献类型：
--
作者：
Jie, X.;Hua, L.;Hua, Z.
建立胶质母细胞瘤-树突状细胞（DC）疫苗制备检测平台，并确定疫苗在临床试验中的有效性。自体成胶质细胞瘤-DC疫苗从手术切除获得的成胶质细胞标本制备。在热休克诱导的胶质母细胞瘤凋亡后，样本用于用外周血来源的DC富集疫苗。对照组采用手术加术后放化疗的常规治疗。治疗组接受胶质母细胞瘤-DC疫苗和常规治疗的组合。观察并记录各组的肿瘤控制、存活率、Karnofsky评分及并发症发生情况等功能免疫指标。DC免疫组外周血CD 3+、CD 3+、CD 4+、CD 4 +/CD 8+、NK细胞比例均显著高于对照组（P < 0.05）。DC疫苗接种后血清IL-2、IL-12和IFN-γ水平显著高于对照组（P < 0.05）。接种9个月后，DC组肿瘤控制率明显高于对照组（P <0. 05），生存率明显高于对照组（P <0. 05），复发时间明显长于对照组（P <0. 05）。治疗后6个月和9个月，DC疫苗接种组的Karnofsky评分优于对照组（P < 0.05）。胶质瘤DC疫苗联合术后放化疗可增强患者的免疫功能，提高肿瘤控制率，延长生存期和复发时间，提高生活质量，为胶质母细胞瘤的治疗提供了一种更有效的干预手段。
Establishment of a detection platform for glioblastoma-dendritic cell (DC) vaccine preparation and to determine the efficacy of the vaccine in a clinical trial. Autologous glioblastoma-DC vaccine was prepared from a glioblast specimen procured from surgical resection. The specimen was used to enrich the vaccine with peripherally blood-derived DCs after heat-shock induced, glioblastoma apoptosis. The control group received conventional treatment of surgery and radio-chemotherapy post-operation. The therapeutic group received a combination of glioblastoma-DC vaccine and conventional therapy. A comparison of the functional immune parameters, including tumor control, rate live time, Karnofsky scores, and complications occurring in each group were observed and recorded. The proportions of peripheral CD3(+), CD3(+)CD4(+), CD4(+)/CD8(+), and NK cells were significantly higher after DC vaccination than the control group (P < 0.05). Serum levels of IL-2, IL-12, and IFN-gamma were significantly higher after DC vaccination than in the control group (P < 0.05). Nine months after vaccination, tumor control rate is significantly improved in the DC group compared with the control group (P < 0.05); survival rate was significantly higher in DC group than in control group (P < 0.05) and the time to relapse was significantly longer in DC group than that in control group (P < 0.05). Karnofsky scores were better in DC vaccination group 6 and 9 months post-treatment compared with the control group (P < 0.05). The combination of glioma DC vaccine and radiotherapy/chemotherapy post-operatively enhances the immune function of patients, increases the tumor control rate, prolongs the survival time and relapse duration, improves the quality of life, and therefore provides a more effective intervention of treating glioblastoma.